A phase II study of bortezomib in combination with rituximab, fludarabine, mitoxantrone, and dexamethasone (VR-FND) for relapsed or refractory follicular lymphoma.
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2014
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Fludarabine; Mitoxantrone; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Apr 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.